Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

Rosemary Barnes; Stephanie Earnshaw; Raoul Herbrecht; Orla Morrissey; Monica Slavin; Eric Bow; Cheryl McDade; Claudie Charbonneau; David Weinstein; Michal Kantecki; Haran Schlamm; Johan Maertens

Journal article

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

Rosemary Barnes, Stephanie Earnshaw, Raoul Herbrecht, Orla Morrissey, Monica Slavin, Eric Bow, Cheryl McDade, Claudie Charbonneau, David Weinstein, Michal Kantecki, Haran Schlamm, Johan Maertens

Clinical Therapeutics | ELSEVIER | Published : 2015

DOI: 10.1016/j.clinthera.2015.03.021

University of Melbourne Researchers

Monica Slavin Author Medicine - Royal Melbourne Hospital

Grants

Funding Acknowledgements

This work was supported by Pfizer Inc. Dr. Earnshaw and Ms. McDade are employees of RTI Health Solutions and were paid consultants to Pfizer Inc in connection with the development of the decision-analytic model and the manuscript. Editorial support for the manuscript was provided by Jane Bryant and Karen Irving of Complete Medical Communications and was funded by Pfizer Inc. Dr. Schlamm is no longer employed by Pfizer Inc.